AFP and hepatocellular carcinoma: These findings could aid in managing HCC patients at discharge and during follow-up, promoting a personalized immunosuppression regimen (e.g., early introduction of everolimus, steroid withdrawal, and calcineurin minimization) and a structured follow-up schedule with regular AFP and PIVKA testing and stricter imaging protocols.